m6A-centered Disease Response Information | M6AREG

General Information of the Disease (ID: M6ADIS0118)

Name	Kidney failure
ICD	ICD-11: GB6Z

Full List of Target Gene(s) of This m6A-centered Disease Response

Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)

Target Info

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	m6A modification is co-regulated by METTL3 and FTO in cadmium-treated cells. Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), LncRNA-PVT1 and m6A modification could be key nodes for cadmium-induced oxidative damage, and highlight their importance as promising preventive and therapeutic targets in cadmium toxicity.
Responsed Disease	Kidney failure [ICD-11: GB6Z]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
In-vitro Model	NIT-1	Insulin tumor	Mus musculus	CVCL_3561
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	m6A modification is co-regulated by METTL3 and FTO in cadmium-treated cells. Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), LncRNA-PVT1 and m6A modification could be key nodes for cadmium-induced oxidative damage, and highlight their importance as promising preventive and therapeutic targets in cadmium toxicity.
Responsed Disease	Kidney failure [ICD-11: GB6Z]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
In-vitro Model	NIT-1	Insulin tumor	Mus musculus	CVCL_3561

Pvt1 oncogene (PVT1)

Target Info

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	m6A modification is co-regulated by METTL3 and FTO in cadmium-treated cells. LncRNA-MALAT1, Pvt1 oncogene (PVT1) and m6A modification could be key nodes for cadmium-induced oxidative damage, and highlight their importance as promising preventive and therapeutic targets in cadmium toxicity.
Responsed Disease	Kidney failure [ICD-11: GB6Z]
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
In-vitro Model	NIT-1	Insulin tumor	Mus musculus	CVCL_3561
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	m6A modification is co-regulated by METTL3 and FTO in cadmium-treated cells. LncRNA-MALAT1, Pvt1 oncogene (PVT1) and m6A modification could be key nodes for cadmium-induced oxidative damage, and highlight their importance as promising preventive and therapeutic targets in cadmium toxicity.
Responsed Disease	Kidney failure [ICD-11: GB6Z]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
In-vitro Model	NIT-1	Insulin tumor	Mus musculus	CVCL_3561

References

Ref 1	Changes and relationship of N(6)-methyladenosine modification and long non-coding RNAs in oxidative damage induced by cadmium in pancreatic Beta-cells. Toxicol Lett. 2021 Jun 1;343:56-66. doi: 10.1016/j.toxlet.2021.02.014. Epub 2021 Feb 24.

Cite M6AREG

S. P. Liu, L. Chen, Y. T. Zhang, Y. Zhou, Y. He, Z. Chen, S. S. Qi, J. Y. Zhu, X. D. Chen, H. Zhang, Y. C. Luo, Y. Q. Qiu, L. Tao*, F. Zhu*. M6AREG: m6A-centered regulation of disease development and drug response. Nucleic Acids Research. 2022 Sep 22;gkac801. PMID: 36134713

Correspondence

Prof. Feng ZHU

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

Prof. Shuiping Liu

School of Pharmacy, Hangzhou Normal University, Hangzhou, China

Visitor Map

Back to top